Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study.
[BACKGROUND] The survival benefit of direct-acting antiviral (DAA) in hepatitis C virus (HCV)-infected patients with or without active hepatocellular carcinoma (HCC) remains debated.
- p-value p < 0.001
- p-value p = 0.007
- 95% CI 0.31-0.66
- 연구 설계 cohort study
APA
Lee TY, Yang SS, et al. (2026). Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study.. European journal of cancer (Oxford, England : 1990), 232, 116109. https://doi.org/10.1016/j.ejca.2025.116109
MLA
Lee TY, et al.. "Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study.." European journal of cancer (Oxford, England : 1990), vol. 232, 2026, pp. 116109.
PMID
41274170
Abstract
[BACKGROUND] The survival benefit of direct-acting antiviral (DAA) in hepatitis C virus (HCV)-infected patients with or without active hepatocellular carcinoma (HCC) remains debated. This study aimed to clarify this issue.
[METHODS] This retrospective nationwide cohort study utilized data from the Taiwan Association for the Study of the Liver (TASL) HCV Registry (TACR) to identify adults with HCC who received DAA therapy for HCV between December 2013 and December 2020. Patients with other viral infections, prior liver transplantation, non-HCC malignancies, or terminal-stage HCC were excluded. The primary outcome was overall survival (OS). The adjusted odds ratio (aOR) for sustained virological response (SVR) and the adjusted hazard ratio (aHR) for OS were calculated.
[FINDINGS] A total of 2205 patients were included: 1771 (80.3 %) without active HCC and 434 (19.7 %) with active HCC. SVR was independently associated with improved OS (aHR 0.45, 95 % CI: 0.31-0.66; p < 0.001). In Barcelona Clinic Liver Cancer (BCLC) stage 0/A, the 3-year OS rate was significantly higher in the SVR group amongst patients with active HCC (71.7 %, 95 % CI 64.6-77.7 % vs. 39.9 %, 95 % CI 15.6-63.5 %; p = 0.007) but non-significantly higher amongst those without active HCC (84.2 %, 95 % CI 81.7-86.4 % vs. 70.0 %, 95 % CI 44.2-85.6 %; p = 0.181). In BCLC stage B/C, the 3-year OS rate was significantly higher in the SVR group amongst patients without active HCC (76.2 %, 95 % CI 70.2-81.2 % vs. 24.7 %, 95 % CI 5.3-51.3 %; p < 0.001) but not amongst those with active HCC (58.6 %, 95 % CI 47.9-67.7 % vs. 57.1 %, 95 % CI 17.2-83.7 %; p = 0.922).
[CONCLUSION] For BCLC stage 0/A HCC, early DAA initiation is recommended, even with active HCC. In BCLC stage B/C, DAA therapy appears most beneficial after tumor control.
[METHODS] This retrospective nationwide cohort study utilized data from the Taiwan Association for the Study of the Liver (TASL) HCV Registry (TACR) to identify adults with HCC who received DAA therapy for HCV between December 2013 and December 2020. Patients with other viral infections, prior liver transplantation, non-HCC malignancies, or terminal-stage HCC were excluded. The primary outcome was overall survival (OS). The adjusted odds ratio (aOR) for sustained virological response (SVR) and the adjusted hazard ratio (aHR) for OS were calculated.
[FINDINGS] A total of 2205 patients were included: 1771 (80.3 %) without active HCC and 434 (19.7 %) with active HCC. SVR was independently associated with improved OS (aHR 0.45, 95 % CI: 0.31-0.66; p < 0.001). In Barcelona Clinic Liver Cancer (BCLC) stage 0/A, the 3-year OS rate was significantly higher in the SVR group amongst patients with active HCC (71.7 %, 95 % CI 64.6-77.7 % vs. 39.9 %, 95 % CI 15.6-63.5 %; p = 0.007) but non-significantly higher amongst those without active HCC (84.2 %, 95 % CI 81.7-86.4 % vs. 70.0 %, 95 % CI 44.2-85.6 %; p = 0.181). In BCLC stage B/C, the 3-year OS rate was significantly higher in the SVR group amongst patients without active HCC (76.2 %, 95 % CI 70.2-81.2 % vs. 24.7 %, 95 % CI 5.3-51.3 %; p < 0.001) but not amongst those with active HCC (58.6 %, 95 % CI 47.9-67.7 % vs. 57.1 %, 95 % CI 17.2-83.7 %; p = 0.922).
[CONCLUSION] For BCLC stage 0/A HCC, early DAA initiation is recommended, even with active HCC. In BCLC stage B/C, DAA therapy appears most beneficial after tumor control.
MeSH Terms
Humans; Carcinoma, Hepatocellular; Male; Liver Neoplasms; Female; Middle Aged; Antiviral Agents; Retrospective Studies; Taiwan; Aged; Sustained Virologic Response; Hepatitis C, Chronic; Hepacivirus; Adult; Hepatitis C; Registries
같은 제1저자의 인용 많은 논문 (5)
- Strategies of upper blepharoplasty in aging patients with involutional ptosis.
- Paranasal Augmentation Using Multi-Folded Expanded Polytetrafluorethylene (ePTFE) in the East Asian Nose.
- Validated Nationwide Scoring System for Hepatocellular Carcinoma Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease.
- Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients: Correspondence to letter to the editor on "Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study".
- Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Correspondence to editorial on "Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study".